ReviewCurrent atherosclerosis reports2020
The Role of the Gut Microbiota in Coronary Heart Disease.
Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effects of Statin Therapy on Circulating Levels of Trimethylamine N-oxide: A Systematic Review and Meta-analysis.Current medicinal chemistry · 2025Pooled it
- Trial
- Effect of CICARE Communication Mode on Disease Uncertainty, Self-Nursing Ability, and Quality of Life in Patients with Coronary Atherosclerotic Heart Disease after Percutaneous Coronary Intervention.Computational and mathematical methods in medicine · 2022Trial
- Traditional Chinese medicine-based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives.Frontiers in cardiovascular medicine · 2026Review
- The Role of the Gut Microbiota in Mental Health and Cognitive Function in Patients with Coronary Atherosclerosis.Nutrients · 2025Review
- Flavonifractor Plautii or Its Metabolite Desaminotyrosine as Prophylactic Agents for Alleviating Myocardial Ischemia/Reperfusion Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Dietary live microorganisms and depression-driven mortality in hypertensive patients: NHANES 2005-2018.Journal of health, population, and nutrition · 2025Article
- A non-invasive prediction model for coronary artery stenosis severity based on multimodal data.Frontiers in physiology · 2025Article
- Multi-omics analysis identifiesFrontiers in microbiology · 2025Article
- The Interplay of Diet, Genome, Metabolome, and Gut Microbiome in Cardiovascular Disease: A Narrative Review.Current medicinal chemistry · 2025Review
- The gut microbiome, chronic kidney disease, and sarcopenia.Cell communication and signaling : CCS · 2024Review
- Bacteriophages and their potential for treatment of metabolic diseases.Journal of diabetes · 2024Review
- Prophylactic supplementation withiMeta · 2024Article
- Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases.Cardiovascular & hematological disorders drug targets · 2024Review
- Associations of systemic inflammation and systemic immune inflammation with serum uric acid concentration and hyperuricemia risk: the mediating effect of body mass index.Frontiers in endocrinology · 2024Article
- Exploring of gut microbiota features in dyslipidemia and chronic coronary syndrome patients undergoing coronary angiography.Frontiers in microbiology · 2024Article
- Gut microbiota and risk of coronary heart disease: a two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- Effects of semaglutide on gut microbiota, cognitive function and inflammation in obese mice.PeerJ · 2024Article
- Gut-Kidney-Heart: A Novel Trilogy.Biomedicines · 2023Review
- ABO gene polymorphisms are associated with acute coronary syndrome and with plasma concentration of HDL-cholesterol and triglycerides.Biomolecules & biomedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review focuses on recent evidence examining the role gut microbiota play in coronary heart disease. It also provides a succinct overview of current and future therapies targeting the gut microbiota for coronary heart disease risk reduction. RECENT
findingsA consensus has been reached that differences exist in the gut microbiotas of patients with coronary heart disease. Studies have shown that the gut microbiota is associated with obesity, diabetes, dyslipidemia, and hypertension, which are risk factors for coronary heart disease. The gut microbiota is involved in mediating basic metabolic processes, such as cholesterol metabolism, uric acid metabolism, oxidative stress, and inflammatory reactions, through its metabolites, which can induce the development of atherosclerosis and coronary heart disease. Interfering with the composition of gut microbiota, supplementing probiotics, and fecal donation are active areas of research to potentially prevent and treat coronary heart disease. Gut microbiota are causally associated with coronary heart disease. We analyzed the gut microbiota's effects on risk factors for coronary heart disease and studied the effects of gut microbiota metabolites on coronary heart disease. Gut microbiota is a potential target for preventing and treating coronary heart disease.
Indexed as
Identifiers
33063240What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.